Evidence map›Paper›PMID 35132597›Full record

ArticleAdvances in experimental medicine and biology2021

Potential Drug Strategies to Target Coronaviruses.

Kasturi Sarkar, Parames C Sil

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Kasturi SarkarDepartment of Microbiology, St. Xavier's College, Kolkata, India.
Parames C SilDepartment of Molecular Medicine, Bose Institute, Kolkata, India. parames@jcbose.ac.in.
Bose Institute · INSt. Xavier's College (Autonomous)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAs the world has witnessed three severe coronavirus outbreaks in the past two decades, including the recent pandemic COVID19, caused by SARS-CoV2, it has become of utmost importance to develop drugs and vaccines against coronaviruses. The previous two outbreaks, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) emerged in China and Saudi Arabia in 2003 and 2012, respectively. COVID19 is considered the worst of all and has taken more than 4 million lives so far and crippled the socioeconomic life of human beings in the entire world. Extensive research is being carried out to find out a solution that will not only help us to fight the current situation but also prepare us to prevent further intervention by similar viruses in the future. Here, we aim to highlight potential drug target sites in coronavirus infection or life cycle in general.

methodsWe have gone through the research papers published on coronavirus, with special emphasis on SARS-CoV, MERS-CoV, and SARS-CoV2, in peer-reviewed journals and tried to identify the possible sites in the coronavirus life cycle which can be used as potential drug targets.

resultsStudies showed that there are several unique enzymes and mechanisms involved in the coronavirus life cycle which can be manipulated to develop drugs against it. However, it has been always a challenge to develop drugs or vaccines against viruses as they utilize the host cell machinery and more difficult against RNA viruses because of their high mutation rate.

conclusionsEffective control of the current (2020) pandemic necessarily depends on the development of either a vaccine or an effective therapeutic agent. In the past, many attempts were taken to develop vaccines after the outbreak of SARS-CoV and MERS-CoV, though no successful vaccine reached to the market as the situation came under control. In the current scenario, many laboratories have developed effective vaccines against SARS-CoV2, which have reduced both the severity of the infection and the rate of mortality considerably. However, world needs to be prepared for similar viral outbreaks in future and research must be continued to develop more effective vaccines and therapeutics against coronaviruses.

Indexed as

COVID-19Middle East Respiratory Syndrome CoronavirusPharmaceutical PreparationsHumansRNA, ViralSARS-CoV-2Pharmaceutical PreparationsRNA, ViralCoronavirusCytokine stormInnate and adaptive immune responseNeutralizing antibodySARSSevere acute respiratory syndromeVaccination

Identifiers

PMID35132597
OpenAlexW4210609051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.